David M A Mann

List of Publications by Year in Descending Order

188 papers	29,760 citations	70 h-index	172 g-index
195 ext. papers	33,996 ext. citations	9.4 avg, IF	6.16 L-index

#	Paper	IF	Citations
188	Ultrastructural and biochemical classification of pathogenic tau, α-synuclein and TDP-43.. *Acta Neuropathologica*, **2022**, 143, 613-640	14.3	1
187	Telephone Interview for Cognitive Status Scores Associate with Cognitive Impairment and Alzheimer's Disease Pathology at Death. *Journal of Alzheimer's Disease*, **2021**, 84, 609-619	4.3	0
186	Human tauopathy-derived tau strains determine the substrates recruited for templated amplification. *Brain*, **2021**, 144, 2333-2348	11.2	4
185	Early changes in visuospatial episodic memory can help distinguish primary age-related tauopathy from Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **2021**, 47, 1114-1116	5.2	5
184	Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death. *International Journal of Geriatric Psychiatry*, **2021**, 36, 713-721	3.9	2
183	Amyloid-PET-Positive Patient With bvFTD: Wrong Diagnosis, False Positive Scan, or Copathology?. *Neurology: Clinical Practice*, **2021**, 11, e952-e955	1.7	1
182	Comparison of Common and Disease-Specific Post-translational Modifications of Pathological Tau Associated With a Wide Range of Tauopathies. *Frontiers in Neuroscience*, **2020**, 14, 581936	5.1	18
181	Influence of APOE genotype in primary age-related tauopathy. *Acta Neuropathologica Communications*, **2020**, 8, 215	7.3	2
180	Evaluation of F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in rodents and in human tissue. *Theranostics*, **2020**, 10, 7938-7955	12.1	3
179	Symmetric dimethylation of poly-GR correlates with disease duration in C9orf72 FTLD and ALS and reduces poly-GR phase separation and toxicity. *Acta Neuropathologica*, **2020**, 139, 407-410	14.3	20
178	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. *Acta Neuropathologica*, **2020**, 139, 717-734	14.3	8
177	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. *Acta Neuropathologica Communications*, **2020**, 8, 5	7.3	15
176	A Comparative Study of Pathological Outcomes in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age and Brains for Dementia Research Cohorts. *Journal of Alzheimer's Disease*, **2020**, 73, 619-632	4.3	5
175	The Contribution of Vascular Pathology Toward Cognitive Impairment in Older Individuals with Intermediate Braak Stage Tau Pathology. *Journal of Alzheimer's Disease*, **2020**, 77, 1005-1015	4.3	1
174	Influence of Genotype on Mortality and Cognitive Impairment. *Journal of Alzheimer's Disease Reports*, **2020**, 4, 281-286	3.3	4
173	No association between head injury with loss of consciousness and Alzheimer disease pathology-Findings from the University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. *International Journal of Geriatric Psychiatry*, **2019**, 34, 1262-1266	3.9	1
172	Heritability and genetic variance of dementia with Lewy bodies. *Neurobiology of Disease*, **2019**, 127, 492-501	7.9	15

171	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. *Acta Neuropathologica*, **2019**, 137, 879-899	14.3	50
170	The role of lysosomes and autophagosomes in frontotemporal lobar degeneration. *Neuropathology and Applied Neurobiology*, **2019**, 45, 244-261	5.2	12
169	Association between semantic dementia and progressive supranuclear palsy. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 115-117	5.5	6
168	Genetic meta-analysis of diagnosed Alzheimer disease identifies new risk loci and implicates A tau, immunity and lipid processing. *Nature Genetics*, **2019**, 51, 414-430	36.3	917
167	A comprehensive screening of copy number variability in dementia with Lewy bodies. *Neurobiology of Aging*, **2019**, 75, 223.e1-223.e10	5.6	10
166	Scores Obtained from a Simple Cognitive Test of Visuospatial Episodic Memory Performed Decades before Death Are Associated with the Ultimate Presence of Alzheimer Disease Pathology. *Dementia and Geriatric Cognitive Disorders*, **2018**, 45, 79-90	2.6	6
165	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 548-558	24.1	60
164	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer disease. *Neurobiology of Aging*, **2018**, 62, 244.e1-244.e8	5.6	25
163	The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer disease in individuals with Down syndrome. *Acta Neuropathologica Communications*, **2018**, 6, 56	7.3	48
162	Raman Spectroscopy to Diagnose Alzheimer Disease and Dementia with Lewy Bodies in Blood. *ACS Chemical Neuroscience*, **2018**, 9, 2786-2794	5.7	38
161	Pathological Correlates of Cognitive Impairment in The University of Manchester Longitudinal Study of Cognition in Normal Healthy Old Age. *Journal of Alzheimers Disease*, **2018**, 64, 483-496	4.3	19
160	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. *Lancet Neurology, The*, **2018**, 17, 64-74	24.1	121
159	Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance. *Neurobiology of Aging*, **2018**, 63, 54-64	5.6	28
158	Immunohistochemical detection of C9orf72 protein in frontotemporal lobar degeneration and motor neurone disease: patterns of immunostaining and an evaluation of commercial antibodies. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2018**, 19, 102-111	3.6	5
157	Prevalence of amyloid- pathology in distinct variants of primary progressive aphasia. *Annals of Neurology*, **2018**, 84, 729-740	9.4	74
156	Patterns and severity of vascular amyloid in Alzheimer disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer disease. *Acta Neuropathologica*, **2018**, 136, 569-587	14.3	35
155	Lysosomes, autophagosomes and Alzheimer pathology in dementia with Lewy body disease. *Neuropathology*, **2018**, 38, 347	2	4
154	Early changes in extracellular matrix in Alzheimer disease. *Neuropathology and Applied Neurobiology*, **2017**, 43, 167-182	5.2	85

153	Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. *Brain Pathology*, **2017**, 27, 723-736	6	76
152	Semantic dementia, progressive non-fluent aphasia and their association with amyotrophic lateral sclerosis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 711-712	5.5	20
151	Reply: Atherosclerosis and vascular cognitive impairment neuropathological guideline. *Brain*, **2017**, 140, e13	11.2	1
150	Differential diagnosis of Alzheimer's disease using spectrochemical analysis of blood. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E7929-E7938	11.5	79
149	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature Genetics*, **2017**, 49, 1373-1384	36.3	508
148	Heterogeneous ribonuclear protein E2 (hnRNP E2) is associated with TDP-43-immunoreactive neurites in Semantic Dementia but not with other TDP-43 pathological subtypes of Frontotemporal Lobar Degeneration. *Acta Neuropathologica Communications*, **2017**, 5, 54	7.3	8
147	Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene. *Acta Neuropathologica Communications*, **2017**, 5, 31	7.3	13
146	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. *Neurobiology of Aging*, **2017**, 49, 214.e13-214.e15	5.6	10
145	Extended post-mortem delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: a study from the Brains for Dementia Research Network Neuropathology Study Group, UK. *Acta Neuropathologica*, **2016**, 132, 753-755	14.3	13
144	Co-Occurrence of Language and Behavioural Change in Frontotemporal Lobar Degeneration. *Dementia and Geriatric Cognitive Disorders Extra*, **2016**, 6, 205-13	2.5	31
143	Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. *Acta Neuropathologica*, **2016**, 131, 267-280	14.3	122
142	ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. *EBioMedicine*, **2016**, 9, 278-292	8.8	28
141	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiology of Aging*, **2016**, 38, 214.e7-214.e10	5.6	49
140	Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. *Neuropathology and Applied Neurobiology*, **2016**, 42, 242-54	5.2	48
139	Pathological tau deposition in Motor Neurone Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. *Acta Neuropathologica Communications*, **2016**, 4, 33	7.3	26
138	Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. *Brain*, **2016**, 139, 2957-2969	11.2	141
137	Magnetite pollution nanoparticles in the human brain. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 10797-801	11.5	516
136	Plasma levels of progranulin and interleukin-6 in frontotemporal lobar degeneration. *Neurobiology of Aging*, **2015**, 36, 1603.e1-4	5.6	22

135	p62/SQSTM1 analysis in frontotemporal lobar degeneration. *Neurobiology of Aging*, **2015**, 36, 1603.e5-9	5.6	10
134	Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. *Neurobiology of Disease*, **2015**, 79, 81-99	7.5	83
133	UBQLN2 variant of unknown significance in frontotemporal lobar degeneration. *Neurobiology of Aging*, **2015**, 36, 546.e15-6	5.6	12
132	TREM2 analysis and increased risk of Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 546.e9-13	5.6	33
131	Accumulation of dipeptide repeat proteins predates that of TDP-43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. *Neuropathology and Applied Neurobiology*, **2015**, 41, 601-12	5.2	53
130	Histone deacetylases (HDACs) in frontotemporal lobar degeneration. *Neuropathology and Applied Neurobiology*, **2015**, 41, 245-57	5.2	8
129	Dipeptide repeat protein toxicity in frontotemporal lobar degeneration and in motor neurone disease associated with expansions in C9ORF72-a cautionary note. *Neurobiology of Aging*, **2015**, 36, 1224-6	5.6	9
128	Small deletion in C9orf72 hides a proportion of expansion carriers in FTLD. *Neurobiology of Aging*, **2015**, 36, 1601.e1-5	5.6	17
127	Do NIA-AA criteria distinguish Alzheimer's disease from frontotemporal dementia?. *Alzheimer's and Dementia*, **2015**, 11, 207-15	1.2	18
126	Patterns of microglial cell activation in frontotemporal lobar degeneration. *Neuropathology and Applied Neurobiology*, **2014**, 40, 686-96	5.2	50
125	Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet Neurology, The*, **2014**, 13, 686-99	24.1	207
124	C9ORF72 in dementia with Lewy bodies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2014**, 85, 1435-6	5.5	11
123	Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **2014**, 40, 136-48	5.2	34
122	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*, **2014**, 23, 6139-46	5.6	152
121	No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. *Neuropathology and Applied Neurobiology*, **2014**, 40, 844-54	5.2	17
120	Amyloid or tau: the chicken or the egg?. *Acta Neuropathologica*, **2013**, 126, 609-13	14.3	30
119	Prion-like properties of pathological TDP-43 aggregates from diseased brains. *Cell Reports*, **2013**, 4, 124-34	8.6	322
118	Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease. *Brain Research*, **2013**, 1504, 16-24	3.7	35

117	Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. *Acta Neuropathologica Communications*, **2013**, 1, 68	7.3	131
116	Extensive deamidation at asparagine residue 279 accounts for weak immunoreactivity of tau with RD4 antibody in Alzheimer disease brain. *Acta Neuropathologica Communications*, **2013**, 1, 54	7.3	47
115	Pathological assessments for the presence of hexanucleotide repeat expansions in C9ORF72 in Alzheimer disease. *Acta Neuropathologica Communications*, **2013**, 1, 50	7.3	10
114	Prion-like spreading of pathological synuclein in brain. *Brain*, **2013**, 136, 1128-38	11.2	551
113	Nuclear carrier and RNA-binding proteins in frontotemporal lobar degeneration associated with fused in sarcoma (FUS) pathological changes. *Neuropathology and Applied Neurobiology*, **2013**, 39, 157-65	5.2	18
112	Frontotemporal dementia with amyotrophic lateral sclerosis: a clinical comparison of patients with and without repeat expansions in C9orf72. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*, **2013**, 14, 172-6	3.6	44
111	Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. *Neurology*, **2013**, 80, 1881-7	6.5	60
110	A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. *JAMA Neurology*, **2013**, 70, 727-35	17.2	285
109	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. *Acta Neuropathologica*, **2012**, 124, 373-82	14.3	69
108	Analysis of the hexanucleotide repeat in C9ORF72 in Alzheimer disease. *Neurobiology of Aging*, **2012**, 33, 1846.e5-6	5.6	36
107	Molecular analysis and biochemical classification of TDP-43 proteinopathy. *Brain*, **2012**, 135, 3380-91	11.2	75
106	Epitope mapping of antibodies against TDP-43 and detection of protease-resistant fragments of pathological TDP-43 in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. *Biochemical and Biophysical Research Communications*, **2012**, 417, 116-21	3.4	17
105	Frontotemporal lobar degeneration in a very young patient is associated with fused in sarcoma (FUS) pathological changes. *Neuropathology and Applied Neurobiology*, **2012**, 38, 101-4	5.2	3
104	Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. *Brain*, **2012**, 135, 693-708	11.2	420
103	A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron*, **2011**, 72, 257-68	13.9	3018
102	Synaptic changes in frontotemporal lobar degeneration: correlation with MAPT haplotype and APOE genotype. *Neuropathology and Applied Neurobiology*, **2011**, 37, 366-80	5.2	8
101	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer disease. *Nature Genetics*, **2011**, 43, 429-35	36.3	1421
100	Pathological correlates of frontotemporal lobar degeneration in the elderly. *Acta Neuropathologica* , **2011**, 121, 365-71	14.3	64

99	Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer disease pathology and is independent of tau, A and TDP-43 pathology. *Acta Neuropathologica*, **2011**, 121, 635-49	14.3	18
98	The most common type of FTLD-FUS (aFTLD-U) is associated with a distinct clinical form of frontotemporal dementia but is not related to mutations in the FUS gene. *Acta Neuropathologica*, **2011**, 122, 99-110	14.3	90
97	A harmonized classification system for FTLD-TDP pathology. *Acta Neuropathologica*, **2011**, 122, 111-3	14.3	656
96	TDP-43 pathological changes in early onset familial and sporadic Alzheimer disease, late onset Alzheimer disease and Down syndrome: association with age, hippocampal sclerosis and clinical phenotype. *Acta Neuropathologica*, **2011**, 122, 703-13	14.3	106
95	What in a name? Neuronal intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration-intermediate filament (FTLD-IF) or frontotemporal lobar degeneration-fused in sarcoma (FTLD-FUS)?. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 1412-4	5.5	12
94	The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. *Brain*, **2011**, 134, 2478-92	11.2	178
93	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. *Nature Genetics*, **2010**, 42, 234-9	36.3	361
92	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. *Acta Neuropathologica*, **2010**, 119, 1-4	14.3	711
91	Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. *Acta Neuropathologica*, **2010**, 120, 55-66	14.3	77
90	Effect of topographical distribution of synuclein pathology on TDP-43 accumulation in Lewy body disease. *Acta Neuropathologica*, **2010**, 120, 789-801	14.3	24
89	Increased TDP-43 protein in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. *Acta Neuropathologica*, **2009**, 117, 55-62	14.3	148
88	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. *Acta Neuropathologica*, **2009**, 117, 15-8	14.3	325
87	TDP-43 in ubiquitinated inclusions in the inferior olives in frontotemporal lobar degeneration and in other neurodegenerative diseases: a degenerative process distinct from normal ageing. *Acta Neuropathologica*, **2009**, 118, 359-69	14.3	25
86	Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. *Acta Neuropathologica*, **2009**, 118, 647-58	14.3	65
85	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer disease. *Nature Genetics*, **2009**, 41, 1088-93	36.3	2018
84	Ubiquitin associated protein 1 is a risk factor for frontotemporal lobar degeneration. *Neurobiology of Aging*, **2009**, 30, 656-65	5.6	29
83	Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. *Brain*, **2008**, 131, 721-31	11.2	163
82	Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. *Psychopharmacology*, **2008**, 196, 603-10	4.7	50

81	TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration. *Acta Neuropathologica*, **2008**, 116, 141-6	14.3	115
80	Progressive anomia revisited: focal degeneration associated with progranulin gene mutation. *Neurocase*, **2007**, 13, 366-77	0.8	12
79	DJ-1 (PARK7) is associated with 3R and 4R tau neuronal and glial inclusions in neurodegenerative disorders. *Neurobiology of Disease*, **2007**, 28, 122-32	7.5	31
78	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. *Acta Neuropathologica*, **2007**, 113, 521-33	14.3	252
77	Frontotemporal lobar degeneration: clinical and pathological relationships. *Acta Neuropathologica*, **2007**, 114, 31-8	14.3	244
76	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathologica*, **2007** , 114, 5-22	14.3	837
75	Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2007**, 78, 350-5	5.5	74
74	TDP-43 gene analysis in frontotemporal lobar degeneration. *Neuroscience Letters*, **2007**, 419, 1-4	3.3	40
73	Cognitive phenotypes in Alzheimer's disease and genetic risk. *Cortex*, **2007**, 43, 835-45	3.8	170
72	Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. *Brain*, **2006**, 129, 3091-102	11.2	166
71	Mutations in progranulin explain atypical phenotypes with variants in MAPT. *Brain*, **2006**, 129, 3124-6	11.2	85
70	TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Biochemical and Biophysical Research Communications*, **2006**, 351, 602-11	3.4	1771
69	Relationships in Alzheimer's disease between the extent of Abeta deposition in cerebral blood vessel walls, as cerebral amyloid angiopathy, and the amount of cerebrovascular smooth muscle cells and collagen. *Neuropathology and Applied Neurobiology*, **2006**, 32, 332-40	5.2	43
68	Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **2006**, 32, 374-87	5.2	31
67	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. *Nature*, **2006**, 442, 916-9	50.4	1549
66	A 3'UTR polymorphism in the oxidized LDL receptor 1 gene increases Abeta40 load as cerebral amyloid angiopathy in Alzheimer's disease. *Acta Neuropathologica*, **2006**, 111, 15-20	14.3	17
65	An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. *Acta Neuropathologica*, **2006**, 111, 329-40	14.3	81
64	Dementia lacking distinctive histology (DLDH) revisited. *Acta Neuropathologica*, **2006**, 112, 551-9	14.3	75

63	Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. *Acta Neuropathologica*, **2006**, 112, 539-49	14.3	264
62	Association study and meta-analysis of low-density lipoprotein receptor related protein in Alzheimer disease. *Neuroscience Letters*, **2005**, 382, 221-6	3.3	27
61	Frontotemporal dementia. *Lancet Neurology, The*, **2005**, 4, 771-80	24.1	434
60	Histopathological changes underlying frontotemporal lobar degeneration with clinicopathological correlation. *Acta Neuropathologica*, **2005**, 110, 501-12	14.3	117
59	The genetics and molecular pathology of frontotemporal lobar degeneration **2005**, 689-701		1
58	Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2004**, 75, 696-9	5.5	22
57	Autopsy proven sporadic frontotemporal dementia due to microvacuolar-type histology, with onset at 21 years of age. *Journal of Neurology, Neurosurgery and Psychiatry*, **2004**, 75, 1337-9	5.5	15
56	The neuropathology of frontotemporal lobar degeneration with respect to the cytological and biochemical characteristics of tau protein. *Neuropathology and Applied Neurobiology*, **2004**, 30, 1-18	5.2	62
55	Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer disease. *Neuropathology and Applied Neurobiology*, **2004**, 30, 46-56	5.2	62
54	Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. *American Journal of Medical Genetics Part A*, **2004**, 125B, 79-82		18
53	No association between polymorphisms in the lectin-like oxidised low density lipoprotein receptor (ORL1) gene on chromosome 12 and Alzheimer disease in a UK cohort. *Neuroscience Letters*, **2004**, 366, 126-9	3.3	13
52	Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene. *Brain*, **2004**, 127, 1415-26	11.2	73
51	Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer disease. *Neuroscience Letters*, **2003**, 352, 137-40	3.3	39
50	Sporadic Pick disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. *Annals of Neurology*, **2002**, 51, 730-9	9.4	130
49	Inherited frontotemporal dementia in nine British families associated with intronic mutations in the tau gene. *Brain*, **2002**, 125, 732-51	11.2	110
48	Cases of Alzheimer disease due to deletion of exon 9 of the presenilin-1 gene show an unusual but characteristic beta-amyloid pathology known as otton wool plaques. *Neuropathology and Applied Neurobiology*, **2001**, 27, 189-96	5.2	31
47	The selective vulnerability of nerve cells in Huntington disease. *Neuropathology and Applied Neurobiology*, **2001**, 27, 1-21	5.2	114
46	Pick disease is associated with mutations in the tau gene. *Annals of Neurology*, **2000**, 48, 859-867	9.4	116

45	Pick disease is associated with mutations in the tau gene **2000**, 48, 859		7
44	The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. *Journal of Neuropathology and Experimental Neurology*, **1999**, 58, 711-8	3.1	121
43	Association of missense and 5splice-site mutations in tau with the inherited dementia FTDP-17. *Nature*, **1998**, 393, 702-5	50.4	2903
42	Amyloid (Abeta) deposition in chromosome 1-linked Alzheimer disease: the Volga German families. *Annals of Neurology*, **1997**, 41, 52-7	9.4	53
41	Atypical amyloid (A beta) deposition in the cerebellum in Alzheimer disease: an immunohistochemical study using end-specific A beta monoclonal antibodies. *Acta Neuropathologica*, **1996**, 91, 647-53	14.3	25
40	Patterns of glial cell activity in fronto-temporal dementia (lobar atrophy). *Neuropathology and Applied Neurobiology*, **1996**, 22, 17-22	5.2	12
39	Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer disease: predominance of Abeta42(43). *Annals of Neurology*, **1996**, 40, 149-56	9.4	196
38	Microglial cells and amyloid beta protein (A beta) deposition; association with A beta 40-containing plaques. *Acta Neuropathologica*, **1995**, 90, 472-7	14.3	48
37	Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. *Annals of Neurology*, **1995**, 37, 294-9	9.4	351
36	Microglial cells and amyloid ? protein (A?) deposition: association with A?40-containing plaques. *Acta Neuropathologica*, **1995**, 90, 472-477	14.3	
35	The topographic distribution of brain atrophy in cortical Lewy body disease: comparison with Alzheimer disease. *Acta Neuropathologica*, **1995**, 89, 178-183	14.3	
34	Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down syndrome from dementia. *NeuroReport*, **1994**, 5, 2583-5	1.7	86
33	The topographic distribution of brain atrophy in frontal lobe dementia. *Acta Neuropathologica*, **1993**, 85, 334-40	14.3	59
32	Deposition of amyloid beta protein in non-Alzheimer dementias: evidence for a neuronal origin of parenchymal deposits of beta protein in neurodegenerative disease. *Acta Neuropathologica*, **1992**, 83, 415-9	14.3	37
31	Progressive language disorder due to lobar atrophy. *Annals of Neurology*, **1992**, 31, 174-83	9.4	231
30	Disease-specific patterns of locus coeruleus cell loss. *Annals of Neurology*, **1992**, 32, 667-76	9.4	402
29	A morphological analysis of senile plaques in the brains of non-demented persons of different ages using silver, immunocytochemical and lectin histochemical staining techniques. *Neuropathology and Applied Neurobiology*, **1990**, 16, 17-25	5.2	48
28	The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down syndrome and Alzheimer disease. *Acta Neuropathologica*, **1990**, 80, 318-27	14.3	122

27	An analysis of the morphology of senile plaques in Down's syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. *Neuropathology and Applied Neurobiology*, **1989**, 15, 317-29	5.2	66
26	Early senile plaques in Down's syndrome brains show a close relationship with cell bodies of neurons. *Neuropathology and Applied Neurobiology*, **1989**, 15, 531-42	5.2	64
25	Neuropathology of Alzheimer's disease: towards an understanding of the pathogenesis. *Biochemical Society Transactions*, **1989**, 17, 73-5	5.1	2
24	The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. *Neuropathology and Applied Neurobiology*, **1988**, 14, 177-95	5.2	124
23	Alzheimer's disease and Down's syndrome. *Histopathology*, **1988**, 13, 125-37	7.3	187
22	The perforant pathway in Down's syndrome. *Annals of Neurology*, **1987**, 21, 613-4	9.4	2
21	Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. *Journal of Neurochemistry*, **1987**, 48, 8-15	6	193
20	The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages. *Neuropathology and Applied Neurobiology*, **1987**, 13, 123-39	5.2	74
19	The nucleus basalis of Meynert in multi-infarct (vascular) dementia. *Acta Neuropathologica*, **1986**, 71, 332-7	14.3	20
18	The topography of plaques and tangles in Down's syndrome patients of different ages. *Neuropathology and Applied Neurobiology*, **1986**, 12, 447-57	5.2	126
17	An ultrastructural analysis of the effects of accumulation of neurofibrillary tangle in pyramidal neurons of the cerebral cortex in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **1986**, 12, 305-19	5.2	45
16	A quantitative study of the ultrastructure of pyramidal neurons of the cerebral cortex in Alzheimer's disease in relationship to the degree of dementia. *Neuropathology and Applied Neurobiology*, **1986**, 12, 321-9	5.2	16
15	Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. *Journal of Intellectual Disability Research*, **1985**, 29 (Pt 2), 125-35	3.2	20
14	Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. *Neuropathology and Applied Neurobiology*, **1984**, 10, 185-207	5.2	283
13	Pathological basis for neurotransmitter changes in Parkinson's disease. *Neuropathology and Applied Neurobiology*, **1983**, 9, 3-19	5.2	140
12	Immunohistochemical staining of senile plaques. *Neuropathology and Applied Neurobiology*, **1982**, 8, 55-61	5.2	42
11	Neurofibrillary pathology and protein synthetic capability in nerve cells in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **1981**, 7, 37-47	5.2	47
10	Nuclear inclusions in Alzheimer's disease. *Neuropathology and Applied Neurobiology*, **1980**, 6, 245-53	5.2	16

9	Changes in the monoamine containing neurones of the human CNS in senile dementia. *British Journal of Psychiatry*, **1980**, 136, 533-41	5.4	248
8	A quantitative study of the glia of the Purkinje cell layer of the cerebellum in mammals. *Neuropathology and Applied Neurobiology*, **1979**, 5, 71-6	5.2	10
7	Granulovacuolar degeneration in pyramidal cells of the hippocampus. *Acta Neuropathologica*, **1978**, 42, 149-51	14.3	20
6	The quantitative assessment of lipofuscin pigment, cytoplasmic RNA and nucleolar volume in senile dementia. *Neuropathology and Applied Neurobiology*, **1978**, 4, 129-35	5.2	80
5	The DNA content of Purkinje cells in mammals. *Journal of Comparative Neurology*, **1978**, 180, 345-7	3.4	29
4	TETRAPLOIDY AND BLINDNESS. *Neuropathology and Applied Neurobiology*, **1977**, 3, 137-140	5.2	1
3	Lipoprotein pigments--their relationship to ageing in the human nervous system. I. The lipofuscin content of nerve cells. *Brain*, **1974**, 97, 481-8	11.2	139
2	The Neuropathology of Alzheimer Disease223-226		
1	The Role of Presenilins in Alzheimer Disease217-218		